In CML, it has been shown that MDM2 is more highly expressed in quiescent CD34+ CML progenitor cells compared to their proliferating counterparts and that MDM2 plays a vital role in mediating TKI resistance in CML. This evidence concerns the gene CD34 and chronic myelogenous leukemia, BCR-ABL1 positive.